2.99

2.40% 0.07

After Hours: 3.05 0.06 +2.01%

Fate Therapeutics Inc (FATE)

Overview News Price History Option Chain Financials Discussions Forecast

Fate Therapeutics Inc stock is traded at $2.99, with a volume of 3.39M. It is up +2.40% in the last 24 hours and up +51.01% over the past month. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Previous Close:

$2.92

Open:

$2.93

24h Volume:

3.39M

Relative Volume:

0.95

Market Cap:

$348.51M

Revenue:

$6.65M

Net Income/Loss:

$-136.32M

P/E Ratio:

-2.6052

EPS:

-1.1477

Net Cash Flow:

$-112.04M

1W Performance:

+23.55%

1M Performance:

+51.01%

6M Performance:

+196.04%

1Y Performance:

+166.96%

1-Day Range:

$2.84

$3.12

1-Week Range:

$2.3834

$3.21

52-Week Range:

$0.91

$3.21

Fate Therapeutics Inc Stock (FATE) Company Profile

Name

Fate Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

858.875.1803

Address

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Employee

161

Twitter

@fatethx

Next Earnings Date

2026-08-11

Latest SEC Filings

FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FATE Fate Therapeutics Inc	2.99	314.71M	6.65M	-136.32M	-112.04M	-1.1477
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-19-26	Resumed	Jefferies	Buy
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral
Jan-06-23	Downgrade	Stifel	Buy → Hold
Jan-06-23	Downgrade	Truist	Buy → Hold
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-10-22	Initiated	Canaccord Genuity	Buy
Aug-18-22	Resumed	Wells Fargo	Overweight
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-11-22	Resumed	BMO Capital Markets	Market Perform
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform
Dec-07-21	Initiated	Cowen	Outperform
Nov-09-21	Upgrade	Citigroup	Neutral → Buy
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight
Jun-07-21	Upgrade	H.C. Wainwright	Neutral → Buy
May-07-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Jefferies	Buy
Feb-26-21	Initiated	BofA Securities	Buy
Feb-26-21	Downgrade	Wedbush	Outperform → Neutral
Feb-11-21	Downgrade	Citigroup	Buy → Neutral
Jan-27-21	Resumed	H.C. Wainwright	Neutral
May-13-20	Initiated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-09-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-30-19	Reiterated	Mizuho	Buy
Dec-09-19	Upgrade	Wells Fargo	Market Perform → Outperform
Nov-12-19	Initiated	SunTrust	Buy
Nov-06-19	Downgrade	Wells Fargo	Outperform → Market Perform
Oct-01-19	Initiated	Stifel	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-19	Initiated	Oppenheimer	Outperform
Jun-13-19	Initiated	Mizuho	Buy
Jun-07-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Buy
May-24-19	Resumed	Citigroup	Buy
Mar-28-19	Initiated	SVB Leerink	Outperform
Jan-03-19	Downgrade	Stephens	Overweight → Equal-Weight
Nov-05-18	Initiated	Jefferies	Buy
Aug-01-18	Initiated	Citigroup	Buy
Mar-06-18	Downgrade	H.C. Wainwright	Buy → Neutral

View All

Fate Therapeutics Inc Stock (FATE) Latest News

Jul 01, 2026

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times

Jul 01, 2026

Fate Therapeutics lines up four investor conferences in Q3 - Stock Titan

Jul 01, 2026

Jun 29, 2026

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com

Jun 29, 2026

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com

Jun 28, 2026

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade

Jun 28, 2026

Jun 26, 2026